Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

BACKGROUND: The intensive study of predictive factors has strongly ameliorated the therapeutic flow-chart of metastatic colorectal cancer (mCRC) by allowing the selection of patients who benefit from specific therapies. For instance, in mRAS (mutated RAS) mCRC patients, anti-EGFR drugs (cetuximab an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottaiano, Alessandro, Scala, Stefania, Santorsola, Mariachiara, Trotta, Anna Maria, D’Alterio, Crescenzo, Portella, Luigi, Clemente, Ottavia, Nappi, Anna, Zanaletti, Nicoletta, De Stefano, Alfonso, Avallone, Antonio, Granata, Vincenza, Notariello, Carmen, Luce, Amalia, Lombardi, Angela, Picone, Carmine, Petrillo, Antonella, Perri, Francesco, Tatangelo, Fabiana, Di Mauro, Annabella, Albino, Vittorio, Izzo, Francesco, Rega, Daniela, Pace, Ugo, Di Marzo, Massimiliano, Chiodini, Paolo, De Feo, Gianfranco, Del Prete, Paola, Botti, Gerardo, Delrio, Paolo, Caraglia, Michele, Nasti, Guglielmo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010802/
https://www.ncbi.nlm.nih.gov/pubmed/33854566
http://dx.doi.org/10.1177/1758835921989223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010802/
https://www.ncbi.nlm.nih.gov/pubmed/33854566
http://dx.doi.org/10.1177/1758835921989223

Ejemplares similares